论文部分内容阅读
目的分析研究甘精胰岛素联合阿卡波糖治疗老年糖尿病的临床效果及安全性,以供临床借鉴。方法 120例老年糖尿病患者纳为研究对象,按照就诊顺序奇偶数分为对照组与观察组,各60例。对照组仅给予甘精胰岛素治疗,观察组使用甘精胰岛素联合阿卡波糖治疗。比较两组患者治疗前后空腹血糖(FPG)、餐后2小时血糖(2 h PG)、糖化血红蛋白(HbA1c)、空腹C肽(FCP)等检测指标值,同时对比两组患者治疗前后体质量指数与治疗过程中不良反应情况。结果治疗后,两组FPG、2 h PG、HbA1c、FCP水平均优于本组治疗前,且观察组均优于对照组,差异均具有统计学意义(P<0.05)。治疗前后两组体质量指数组间比较差异均无统计学意义(P>0.05)。治疗过程中,对照组不良反应发生率为16.67%,观察组不良反应发生率为3.33%,观察组不良反应发生率明显低于对照组,差异具有统计学意义(P<0.05)。结论甘精胰岛素联合阿卡波糖治疗老年糖尿病效果明显,可有效控制血糖,不良反应发生率低,值得临床应用。
Objective To study the clinical efficacy and safety of glargine combined with acarbose in the treatment of senile diabetes mellitus for clinical reference. Methods A total of 120 elderly patients with diabetes mellitus were enrolled in this study. The patients were divided into control group and observation group according to the order of treatment. The control group was given insulin glargine only, and the observation group was treated with insulin glargine and acarbose. The levels of fasting blood glucose (FPG), 2-hour postprandial blood glucose (2h PG), HbA1c and fasting plasma C-peptide (FCP) were compared between the two groups before and after treatment. And adverse reactions during treatment. Results After treatment, the levels of FPG, 2 h PG, HbA1c and FCP in both groups were better than those in the control group before treatment, and the observation group was superior to the control group. The differences were statistically significant (P <0.05). There was no significant difference in body mass index between the two groups before and after treatment (P> 0.05). In the course of treatment, the incidence of adverse reactions in the control group was 16.67%, the incidence of adverse reactions in the observation group was 3.33%, and the incidence of adverse reactions in the observation group was significantly lower than that in the control group (P <0.05). Conclusion Glargine and acarbose treatment of elderly patients with diabetes has obvious effect, which can effectively control blood sugar, the incidence of adverse reactions is low, worthy of clinical application.